利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

39 条记录 (耗时 0.026 秒)

    Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
    1.
    发明授权
    Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers 失效
    纳米颗粒药剂与晶体生长改性剂的共沉淀

    公开(公告)号：US5665331A

    公开(公告)日：1997-09-09

    申请号：US370998

    申请日：1995-01-10

    申请人： Pranab Bagchi ,  Raymond P. Scaringe ,  H. William Bosch

    发明人： Pranab Bagchi ,  Raymond P. Scaringe ,  H. William Bosch

    IPC分类号： A61K9/14 ,  A61K49/04

    CPC分类号： B82Y5/00 ,  A61K49/0485 ,  A61K9/145 ,  Y10S977/745 ,  Y10S977/881 ,  Y10S977/915 ,  Y10S977/927 ,  Y10S977/928

    摘要： This invention describes the coprecipitation of nanoparticulate pharmaceutical agent dispersion via a process that comprises the dissolution of the said pharmaceutical agent in combination with a crystal growth modifier (CGM) in an alkaline solution and then neutralizing the said solution with an acid in the presence of suitable surface-modifying surface-active agent or agents to form a fine particle dispersion of the said pharmaceutical agent, followed by steps of diafiltration clean-up of the dispersion and then concentration of it to a desired level. This process of dispersion preparation leads to microcrystalline particles of Z-average diameters smaller than 400 nm as measured by photon correlation spectroscopy. Various modification of precipitation schemes are described, many of which are suitable for large-scale manufacture of these agent dispersions. It has been discovered that coprecipitation with CGM leads to smaller particle size compared to a case where precipitation is carried out using the pharmaceutical agent alone. Thus, this dispersion of instant invention is expected to have greater bioavailability. The CGM compound is a compound that has at least about 75% of its chemical structure identical to that of the pharmaceutical agent.

    摘要翻译： 本发明描述了纳米颗粒药剂分散体的共沉淀，该方法包括在碱性溶液中将所述药剂与晶体生长调节剂（CGM）组合溶解，然后在适当的存在下用酸中和所述溶液 表面改性表面活性剂或试剂以形成所述药剂的细颗粒分散体，然后将分散体进行渗滤清洗，然后将其浓缩至期望水平。 这种分散制备过程导致通过光子相关光谱测量的Z平均直径小于400nm的微晶颗粒。 描述了各种改性的沉淀方案，其中许多适用于这些试剂分散体的大规模制造。 已经发现，与仅使用药剂进行沉淀的情况相比，CGM的共沉淀导致较小的粒度。 因此，本发明的这种分散体预期具有更大的生物利用度。 CGM化合物是其化学结构的至少约75％与药剂相同的化合物。